Alpine Immune drops as U.S. FDA places cancer study on partial clinical hold

Alpine Immune Sciences

07/03/2022 15:45

** Shares of biopharmaceutical firm  ALPN.O  drop 13.7% to
$6.63, set for their biggest pct fall since May 2021 
    ** Co announces that the U.S. Food and Drug Administration
(FDA) placed a partial clinical hold on its NEON-2 trial
evaluating davoceticept, a drug intended for the treatment of
cancer in adults
    ** The clinical hold was prompted by Alpine's report of a
Grade 5 serious adverse event (patient death) in the trial
    ** No additional patients are to be enrolled until the
partial clinical hold is resolved
    ** Stock currently trades about 30% below its 50-DMA and
around 36% below its 200-DMA, showing bearish signals
    ** Stock has lost 52.5% YTD

 (Reporting by Shashank Nayar in Bengaluru)
 ((Shashank.Nayar@thomsonreuters.com; within U.S. +1 646 223
8780; outside U.S. +91 80 6182 2256;))